Stock Events

Acadia Pharmaceuticals 

$17.19
99
+$0.11+0.64% Wednesday 20:00

Statistics

Day High
17.25
Day Low
16.97
52W High
33.99
52W Low
16.6
Volume
1,027,814
Avg. Volume
1,434,009
Mkt Cap
2.83B
P/E Ratio
-45.95
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.43
-0.19
0.06
0.3
Expected EPS
0.06
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACAD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap355.49B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops drugs that directly compete in the neurological and psychiatric drug markets.
Lilly(Eli) &
LLY
Mkt Cap714.18B
Eli Lilly and Company offers a range of products that target the central nervous system, making it a direct competitor in the psychiatric and neurological drug markets.
Novartis
NVS
Mkt Cap204.8B
Novartis AG has a strong portfolio in neuroscience, competing in the development and marketing of drugs for psychiatric and neurological disorders.
Pfizer
PFE
Mkt Cap146.43B
Pfizer Inc. has a diversified portfolio that includes treatments for neurological conditions, directly competing with Acadia's offerings.
Biogen
BIIB
Mkt Cap28.81B
Biogen Inc. focuses on neurology, developing treatments for diseases like multiple sclerosis and Alzheimer's, areas that overlap with Acadia's focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap14.91B
Teva Pharmaceutical Industries Limited has a broad portfolio that includes CNS (central nervous system) drugs, making it a competitor in the neurological and psychiatric medication market.
Abbvie
ABBV
Mkt Cap287.34B
AbbVie Inc. has a growing interest in neuroscience, including R&D in Parkinson's and Alzheimer's, which competes with Acadia's focus areas.
Merck &
MRK
Mkt Cap318.5B
Merck & Co., Inc. is involved in the development of drugs that target neurological disorders, positioning it as a competitor in the same therapeutic area as Acadia.
Sage Therapeutics
SAGE
Mkt Cap928.05M
Sage Therapeutics, Inc. specializes in CNS disorders, with a focus on developing novel medicines to treat conditions that overlap with Acadia's target markets.
Alkermes
ALKS
Mkt Cap4.13B
Alkermes plc has a focus on central nervous system (CNS) disorders, including schizophrenia and depression, directly competing with some of Acadia's key products.

Analyst Ratings

29.75$Average Price Target
The highest estimate is $39.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Stephen Davis
Employees
597
Country
US
ISIN
US0042251084
WKN
000603035

Listings